BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to BGC-823 cell line is 78
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | CFA and IHC staining followed by FACs and Western Blotting | NA | 0.64 | 1 | 26276718 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by FACs and qRT-PCR and Western Blotting | NA | 0.64 | 1 | 33731207 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs and SFA followed by RT-PCR and Western Blotting | NA | 0.64 | 1 | 28440445 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by FACs and Western Blotting | NA | 0.64 | 1 | 31517391 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.64 | 1 | 34090492 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.64 | 1 | 34350176 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.64 | 1 | 30624124 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs | NA | 0.64 | 1 | 32926650 |
| CD44 | 1681 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31073886 |
| MSI1 | 7330 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | CFA and IHC staining followed by FACs and Western Blotting | NA | 0.64 | 0.0201 | 26276718 |
| PROM1 | 9454 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | MAC followed by qRT-PCR and Western Blotting | NA | 0.6 | 0.7582 | 28218426 |
| PROM1 | 9454 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | Cisplatin | FACs and Western Blotting | NA | 0.6 | 0.7582 | 33635343 |
| PROM1 | 9454 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by FACs and Western Blotting | NA | 0.6 | 0.7582 | 34350176 |
| PROM1 | 9454 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 30624124 |
| PROM1 | 9454 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31073886 |
| ALDH1A1 | 402 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.48 | 0.684 | 34427968 |
| ALDH1A1 | 402 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.684 | 34090492 |
| ALDH1A1 | 402 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 30624124 |
| CD274 | 17635 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | Cisplatin | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 33579380 |
| GLI1 | 4317 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | CFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0308 | 26276718 |
| GLI1 | 4317 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.0308 | 34350176 |
| GLI1 | 4317 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0308 | 30624124 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33731207 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | Cisplatin | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33579380 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28440445 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 34350176 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30624124 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 31517391 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.5461 | 33798550 |
| NANOG | 20857 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34173116 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33731207 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.48 | 0.6448 | 34427968 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | Cisplatin | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33579380 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 28440445 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 34090492 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 34350176 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30624124 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 31517391 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.6448 | 33798550 |
| POU5F1 | 9221 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34173116 |
| SHH | 10848 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | CFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0201 | 26276718 |
| SHH | 10848 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.0201 | 34350176 |
| SHH | 10848 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0201 | 30624124 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 33731207 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5695 | 34427968 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | Cisplatin | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 33579380 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 28440445 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 34350176 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 31517391 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.5695 | 33798550 |
| SOX2 | 11195 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34173116 |
| EPCAM | 11529 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.28 | 0.211 | 34350176 |
| EPCAM | 11529 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs followed by SFA | NA | 0.28 | 0.211 | 31073886 |
| GLI2 | 4318 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.28 | 0.0106 | 34350176 |
| GLI2 | 4318 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.28 | 0.0106 | 34350176 |
| GLI2 | 4318 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 30624124 |
| MYC | 7553 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.1304 | 31517391 |
| SLC38A2 | 13448 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.28 | 0.0011 | 34173116 |
| SMO | 11119 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA and Western Blotting | NA | 0.28 | 0.0212 | 34350176 |
| SMO | 11119 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 30624124 |
| MIR155 | 31542 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0053 | 28440445 |
| MIR122 | 31501 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0042 | 28440445 |
| MIR155 | 31542 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0053 | 28440445 |
| MIR196A1 | 31567 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 28440445 |
| MIR30A | 31624 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0085 | 28440445 |
| MIR30B | 31625 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0053 | 28440445 |
| MIR30C1 | 31626 | HTM/LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0042 | 28440445 |
| MIR200B | 31579 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | qRT-PCR | NA | 0.2 | 0.0032 | 32926650 |
| THY1 | 11801 | LTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs followed by SFA | NA | 0.12 | 0.0371 | 31073886 |
| MIR125A | 31505 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 28440445 |
| MIR139 | 31526 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 28440445 |
| MIR151B | 41588 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 28440445 |
| MIR15B | 31544 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0085 | 28440445 |
| MIR181A1 | 31590 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 28440445 |
| MIR3185 | 38391 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 28440445 |
| MIR424 | 31881 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 28440445 |
| MIR4286 | 38186 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 28440445 |
| MIR4649 | 41852 | HTM | Gastric Cancer | Adenocarcinoma | BGC-823 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 28440445 |